Regeneron, Sanofi rack up a PhIII asthma win for dupilumab; Verastem preps FDA app for duvelisib
→ Regeneron and Sanofi say their trial of Dupixent (dupilumab) hit the primary and key secondary endpoints in a Phase III asthma study. Their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
